Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 21, 2005
- Monitor
March 21, 2005
- Early Data Show Significant Antiplatelet Action for Prasugrel: Sankyo
March 21, 2005
- Novo Nordisk Aims at Yearly Growth of 10%: Mr Eilersen
March 21, 2005
- New Study Results on Oral CCR5 Receptor Antagonist Presented: Ono
March 21, 2005
- BULLETIN
March 21, 2005
- Seikagaku to Focus on Joint Diseases, Glycosaminoglycans in R&D
March 21, 2005
- Norvasc Remains No.1 in 4th Qtr: IMS Survey
March 21, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 21, 2005
- Banyu Aiming for Annual Sales of \350 Bil. at Early Date: Mr Hirate
March 21, 2005
- PRESS SEMINAR
March 21, 2005
- Meiji Seika to Enlist Help of MSs in Marketing Activities
March 21, 2005
- Zepharma on Track to Achieve Initial Business Targets
March 21, 2005
- Kanebo Aiming to Become Leader in Kampo Medicines
March 21, 2005
- Kobashou Aims to Build Nationwide Network by FY2007
March 21, 2005
- Execommunications to Acquire Kobashou's Subsidiary Kics
March 14, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 14, 2005
- Nippon Shinyaku Forecasts 2.1% Growth in Sales for FY2004
March 14, 2005
- PRESS SEMINAR
March 14, 2005
- Mochida's R&D to Focus on Lifestyle Diseases, Chronic Pain
March 14, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…